Hangzhou, November 29, 2024 – The First Affiliated Hospital of Zhejiang University School of Medicine recently held the clinical launch meeting for an expansion of the investigator-initiated clinical trial (IIT) to include relapsed or refractory indolent B-cell non-Hodgkin lymphoma (r/r B-iNHL) as a new indication for Leman Biotech's metabolically armed CD19 CAR-T therapy, Meta10-19 therapy. The clinical protocol focuses on preparing allogeneic CAR-T cells using fully matched or partially matched donor lymphocytes, aiming to provide more patients with timely and high-quality CAR-T therapy.
Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (r/r B-iNHL)
Indolent non-Hodgkin lymphoma (iNHL), which includes follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and other variants, is characterized by slow tumor growth and relatively low malignancy. However, these lymphomas have a long natural course with a high rate of relapse, making them challenging to cure completely. While current treatment options can provide remission for some patients, significant challenges remain:
Given these challenges, there is a significant need for more effective treatments for r/r B-iNHL patients that not only extend survival but also improve their quality of life.
Allogeneic CAR-T Cell Preparation from Fully Matched/Partially Matched Donor Lymphocytes
In patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) and those with high tumor burden or who have undergone multiple lines of treatment, creating an effective autologous CAR-T product can be challenging. This is especially true for patients who experience poor blood counts or other conditions that make autologous CAR-T cell collection unfeasible. In such cases, the allogeneic CAR-T cell approach offers a solution by using donor lymphocytes—either fully matched or partially matched—to generate CAR-T cells. This strategy can effectively address the risk of production failure or delays in treatment, ensuring that more patients can benefit from CAR-T therapy in a timely manner.
Patient Recruitment Information
1. Introduction to Meta10-19 Injection
Meta10-19 Injection, a metabolically armed CD19-targeted CAR-T therapy, represents a significant advancement in cancer immunotherapy. Developed by Leman Biotech, Meta10-19 is based on a groundbreaking metabolic reprogramming technology from the Swiss Federal Institute of Technology Lausanne (EPFL). Preliminary studies have shown that this technology allows CAR-T cells to resist exhaustion and maintain continuous activation and proliferation within the tumor microenvironment. In various preclinical mouse models, Meta10-19 CAR-T cells demonstrated the ability to clear tumors completely and prevent relapse.
Meta10-19’s ultra-low dosage requirements—potentially one-thousandth (1‰) of the traditional dose—make it a promising treatment option with an improved safety profile. This advance could significantly enhance the complete response (CR) rates in hematologic cancers, offering better outcomes with fewer side effects.
2. Indications
3. Contact Information
The First Affiliated Hospital of Zhejiang University School of Medicine
Investigator: Dr. Huang He
Outpatient Clinics:
Investigator: Dr. Y ongxian Hu
Outpatient Clinics:
Phone: +86 0571-87233782
WeChat: CARTcells
Address: Doctor's Office, Bone Marrow Transplantation Center, Hematology Department, East Wing, 6th Floor, Building 3, Headquarters Phase I (Yuhang Campus), First Affiliated Hospital of Zhejiang University School of Medicine.
